In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.

The payment was triggered because Kura dosed the first AML patient in a Phase III trial of the menin inhibitor.

AGC Biologics will help the company develop and manufacture RDP-101 in line with FDA standards and for the commercial market.

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

The firm also said this week it will conduct a pivotal study next year of its PRMT5 inhibitor in MTAP-deleted pancreatic cancer.

In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.

NEW YORK – Oncologists attending the European Society for Medical Oncology Congress over the past few days got a glimpse of the next crop of KRAS inhibitors, including treatments targeting KRAS G12C ...

NEW YORK – In a call to discuss the firm's Q3 earnings Thursday morning, Roche executives touted results from the Phase III evERA trial showing a benefit for certain advanced breast cancer patients ...